Get the Stockscreener App
8.236
3.78%
-0.324
Ars Pharmaceuticals Inc stock is traded at $8.236, with a volume of 647.04K.
It is down -3.78% in the last 24 hours and down -3.78% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$8.56
Open:
$8.58
24h Volume:
647.04K
Relative Volume:
0.36
Market Cap:
$819.25M
Revenue:
$98.99M
Net Income/Loss:
$-197.98M
P/E Ratio:
-4.1145
EPS:
-2.0017
Net Cash Flow:
$-175.32M
1W Performance:
-3.78%
1M Performance:
-3.78%
6M Performance:
-26.13%
1Y Performance:
-50.14%
1-Day Range:
$8.18
$8.6646
1-Week Range:
$7.895
$8.6646
52-Week Range:
$6.66
$18.63
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.25 | 795.42M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals plunges 23% as Neffy fails to secure insurance coverage - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud - Business Wire
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals - The National Law Review
(SPRY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) dropped from Russell 2000 Defensive Index - marketscreener.com
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) - PR Newswire
Micron Stock And 2 Fast Growth Picks With Major Catalysts Ahead - Sahm
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices - Yahoo Finance
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - The Killeen Daily Herald
Levi & Korsinsky Announces Investigation of Securities Claims Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Price to earnings forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Price to sales forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.moomoo - Moomoo
Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dadoo Rajeev - Moomoo
ARS Pharmaceuticals (SPRY) director Laura Shawver receives 30,000 stock options award - Stock Titan
ARS Pharmaceuticals (SPRY) director receives grant of 30,000 stock options at $10.54 - Stock Titan
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kelly Michael - Moomoo
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Islam Saqib - Moomoo
ARS Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director SCHNEIDER PHILLIP M - Moomoo
Enterprise value to EBITDA forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Price to book forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
Price to sales forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Enterprise value to EBIT forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY - TradingView
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High - Sahm
Shareholders at ARS Pharmaceuticals (SPRY) back board, auditor and annual say-on-pay - Stock Titan
ARS Pharma: Strong Growth Meets A Coverage Wall (NASDAQ:SPRY) - Seeking Alpha
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins - Benzinga
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - Moomoo
ARS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SPRY) - TradingView
Cantor Fitzgerald keeps Overweight on ARS Pharmaceuticals stock By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
SPRY Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald keeps Overweight on ARS Pharmaceuticals stock - Investing.com
ARS Pharmaceuticals Updates Neffy Coverage Outlook, Cuts 2026 Costs - marketscreener.com
ARS Pharmaceuticals Inc (SPRY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage - Sahm
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView
ARS Pharmaceuticals lowers 2026 expenses, no new payer wins - Investing.com UK
Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo
Shares of ARS Pharmaceuticals Fall After No New Commercial Insurers Add Neffy - Moomoo
ARS Pharmaceuticals lowers 2026 expenses, no new payer wins By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Provides Commercial and Financial Updates - Caledonian Record
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jun 12 '26 |
Sale |
10.00 |
25,000 |
250,000 |
12,176 |
| Fitzpatrick Alexander A | Chief Legal Officer |
Jun 12 '26 |
Sale |
10.00 |
3,355 |
33,550 |
90,910 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):